Bromocriptine in the treatment of hypogonadism and male impotence.
A rapid, practical diagnostic scheme is the key to selecting proper candidates for treatment with bromocriptine. The evaluation centres around assays for prolactin and follicle stimulating hormone, polytomography and computerised axial tomography of the sella turcica and parasellar regions, and the ergot alkaloid, bromocriptine. Additionally, bromocriptine is of significant value in the treatment of men and women with hypogonadotrophic hypogonadism. Approximately 80% of patients with hypogonadotrophic hypogadism and hyperprolactinaemia will respond favorably to bromocriptine therapy. In women who conceive during such treatment there appears to be no increase in the rate of spontaneous abortion, of multiple gestations or of congenital anomalies. Bromocriptine appears to be of little value in the treatment of male impotence unless hyperprolactinaemia is a component of the disease. Side affects are usually mild and transient. Following the discontinuation of therapy most patients have a recurrence of hyperprolactinaemia and hypogonadism.
D001971:Bromocriptine / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D011388:Prolactin / Q000097:blood
D001971:Bromocriptine; D011388:Prolactin